



Dec. 4, 2014

Contact:

Liz Dowling (Medical & Consumer Media)
Dowling & Dennis Public Relations
415-388-2794
Liz@DowlingDennis.net

Matt Clawson (Financial Media)
Pure Communications
949-370-8500
Matt@PureCommunications.com

Agendia's MammaPrint and BluePrint Tests to Be Highlighted at San Antonio Breast Cancer Symposium

Expert Symposium Panel Will Offer Insights Into How Functional Molecular Subtypes Can Better Individualize Treatment

IRVINE, CA and AMSTERDAM, THE NETHERLANDS – New breast cancer research on Agendia's MammaPrint® and BluePrint® genomic tests will be presented in scientific posters at the upcoming 2014 San Antonio Breast Cancer Symposium (#SABCS14), Dec. 9-13.

Agendia will also offer an expert panel symposium on "The Role of Molecular Subtypes and Emerging Research in the Management of Breast Cancer." The panel will be moderated by Adam Brufsky, MD, PhD, of the University of Pittsburgh Medical Center. Panelists will be Massimo Cristofanilli, MD, FACP, of Thomas Jefferson University; Patrick Whitworth, MD, of Nashville Breast Cancer Center, and Fatima Cardoso, MD, of Champalimaud Clinical Centre (Lisbon, Portugal).

Symposium panelists will provide insight into how to formulate individualized approaches to both neoadjuvant and adjuvant therapy, and how to develop an evidence-based approach to clinical decision making in patients with discordant pathological factors. For more information about this event on Thursday, Dec. 11 at 2 p.m., please inquire at the Agendia conference Booth #518.

Among SABCS scientific posters featuring molecular breast cancer tests from Agendia are several drawing upon data from the ongoing I-SPY 2, MINDACT, PROMIS, MINT and NBRST studies. "These posters substantially contribute to the science behind Agendia's tests. They again demonstrate our tests' clinical utility and their significant potential to improve the understanding and treatment of breast cancer," said oncologist Neil Barth, MD, FACP, Agendia's Chief Medical Officer.

Among the Agendia-related poster presentations at SABCS and their authors are:

Thursday, December 11, 2014

Poster P3-06-05: Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 TRIAL.

Authors: D.M. Wolf, Ch. Yau, A. Sanil, A. Daemen, L. Heiser, J. Gray, L. Brown-Swigart, S. Flynn, G. Hirst, I-SPY 2 TRIAL Investigators, M. Buxton, A. DeMichele, N. Hylton, F. Symmans, D. Yee, M. Paoloni, L. Esserman, D. Berry, H. Rugo, O. Olapade, L. van 't Veer

Exhibit Halls A-B, Time 5:00 – 7:00 p.m.

P3-06-37: I-SPY 2 Qualifying Biomarker Evaluation (QBE): The Challenge and Opportunity for Interrogating Predicted Pathways in an Adaptive Design Biomarker Rich Trial

Authors: C. Yau, D. Wolf, A. Sanil, L. van 't Veer, E.F. Petricoin, M. Buxton, J. Gray, A. DeMichele, M. Hogarth, N. Hylton, J. Perlmutter, M. Paoloni, F. Symmans, D. Yee, D. Berry, L. Esserman

Exhibit Halls A-B, Time 5:00 – 7:00 pm

Friday, December 12, 2014

Poster P4-11-08: Pathological assessment of discordant cases for molecular (Blueprint and MammaPrint) vs clinical subtypes for breast cancer, among 6,694 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial.

Authors: Giuseppe Viale, Leen Slaets, Femke de Snoo, Jan Bogaerts, Laura J. van 't Veer, Emiel J. Rutgers, Martine J. Piccart-Gebhart, Jeroen van den Akker, Lisette Stork-Sloots, Leila Russo, Patrizia Dell'Orto, Fatima Cardoso on behalf of the TRANSBIG Consortium & the MINDACT investigators

Exhibit Halls A-B, Time 7:30 – 9:00 am

Poster OT3-3-01: PROMIS: PRospective study Of MammaPrint in breast cancer patients with an Intermediate recurrence Score (PROMIS).

Authors: Hatem Soliman, Sarah Untch, Lisette Stork-Sloots

Exhibit Halls A-B, Time 5:00 – 7:00 pm



Authors: C.C. Cox, P. Blumencranz, R. Saez, R. Wesolowski, W. Dooley, L. Stork-Sloots, F. de Snoo, S. Untch, E. Avisar

Exhibit Halls A-B, Time 5:00 – 7:00 pm

Saturday, December 13, 2014

Poster P6-08-22: Functional subtyping with BluePrint 80-gene profile identifies two distinct triple positive subtypes with and without trastuzumab/chemo-sensitivity: Implications for treatment from the NBRST registry.

Authors: Pat Whitworth, Jennifer Beatty, Paul Baron, Paul Richards, James V Pellicane, Angela Mislowsky, Charles Nash, Laura A Lee, Mary Murray, Femke de Snoo, Lisette Stork-Sloots, Sarah Untch, Mark Gittleman, Stephanie Akbari, Peter Beitsch

Exhibit Hall C, Time 7:30 – 9:00 am

MammaPrint is the first FDA-cleared test to determine recurrence risk in breast cancer patients. The Agendia tests have substantial insurance coverage encompassing an estimated 200 million lives, including coverage by Medicare and regional and national insurers.

The 70-gene MammaPrint test, a second-generation breast cancer recurrence assay, provides definitive High Risk or Low Risk information about breast cancer recurrence, with no “intermediate” results. Agendia’s companion BluePrint test is the only widely available assay that provides functional molecular subtypes. It provides enhanced information about which patients may or may not respond to neoadjuvant (preoperative) therapy and also assists physicians and their patients in determining the best course for therapy. To learn more about the tests, SABCS attendees can visit Booth #518.

Resources for further reference

- Independent comparison validates [molecular subtyping](#) (includes video)
- RASTER prospective outcome [study](#) and [press release](#)
- MammaPrint valid up to 25 years [press release](#)

About Agendia:

Agendia is a leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. MammaPrint is the only breast cancer recurrence assay backed by peer-reviewed, prospective outcome data. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from either hormonal or combination therapy, and which



patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.

In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and the MINDACT trials. For more information, visit www.agendia.com.

-- END --